Edith Szafer‐Glusman

1.8k total citations · 1 hit paper
58 papers, 829 citations indexed

About

Edith Szafer‐Glusman is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Edith Szafer‐Glusman has authored 58 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pathology and Forensic Medicine, 31 papers in Genetics and 23 papers in Oncology. Recurrent topics in Edith Szafer‐Glusman's work include Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (30 papers) and CAR-T cell therapy research (12 papers). Edith Szafer‐Glusman is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (30 papers) and CAR-T cell therapy research (12 papers). Edith Szafer‐Glusman collaborates with scholars based in United States, Australia and Italy. Edith Szafer‐Glusman's co-authors include Elizabeth A. Punnoose, Maria Grazia Giansanti, Margaret T. Fuller, Salomé Lalvée, Marius Ilié, Éric Selva, Paul Hofman, Charles‐Hugo Marquette, Véronique Hofman and Alessandra Tedeschi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Development.

In The Last Decade

Edith Szafer‐Glusman

51 papers receiving 825 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers

Countries citing papers authored by Edith Szafer‐Glusman

Since Specialization

Citations

This map shows the geographic impact of Edith Szafer‐Glusman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edith Szafer‐Glusman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edith Szafer‐Glusman more than expected).

Fields of papers citing papers by Edith Szafer‐Glusman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edith Szafer‐Glusman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edith Szafer‐Glusman. The network helps show where Edith Szafer‐Glusman may publish in the future.

Co-authorship network of co-authors of Edith Szafer‐Glusman

This figure shows the co-authorship network connecting the top 25 collaborators of Edith Szafer‐Glusman. A scholar is included among the top collaborators of Edith Szafer‐Glusman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edith Szafer‐Glusman. Edith Szafer‐Glusman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study 2025 ·The Lancet Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, (unknown), Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	9
2	CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, Anita Szőke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	4
3	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. 2024 ·Journal of Clinical Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Rubén Fernández-Álvarez, Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	4
4	CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, Ryan Jacobs, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan O’Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis Carney, (unknown), Javier de la Serna, Edith Szafer‐Glusman, Cathy Zhou, (unknown), James P. Dean, Paolo Ghia, Constantine S. Tam	0
5	Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, (unknown), Lynne Neumayr, James Dean, Paolo Ghia, Thomas J. Kipps	5
6	Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Wojciech Jurczak, Michael Wang, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, (unknown), Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	0
7	Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, Ryan Jacobs, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan O’Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis Carney, (unknown), Javier de la Serna, Edith Szafer‐Glusman, Cathy Zhou, (unknown), James P. Dean, Paolo Ghia, Constantine S. Tam	0
8	FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY 2023 ·Hematological Oncology ·Paolo Ghia, John N. Allan, Tanya Siddiqi, William G. Wierda, Constantine S. Tam, Carol Moreno, Alessandra Tedeschi, Edith Szafer‐Glusman, Cathy Zhou, (unknown), James P. Dean, Andreı̈ Szöke, Paul M. Barr	1
9	PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2 2023 ·Hematological Oncology ·Laurie H. Sehn, Martine E.D. Chamuleau, Georg Lenz, Michael Roost Clausen, Corinne Haïoun, Koji Izutsu, Andrew Davies, Jun Zhu, Toshihiko Oki, Edith Szafer‐Glusman, (unknown), Hung‐Yi Chiou, David Ipe, (unknown), Jian Wu, Gilles Salles	4
10	Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study 2023 ·Blood Advances ·Carol Moreno, (unknown), Constantine S. Tam, Andrew Grigg, Lydia Scarfò, Thomas J. Kipps, (unknown), Raghuveer Singh Mali, Cathy Zhou, James P. Dean, Edith Szafer‐Glusman, Michael Y. Choi	10
11	Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax 2023 ·Clinical Cancer Research ·Nitin Jain, Lisa J. Croner, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Xavier C. Badoux, Karl Eckert, Leo W.K. Cheung, (unknown), James P. Dean, Edith Szafer‐Glusman, John F. Seymour	20
12	Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody 2023 ·Hematological Oncology ·David S. Soong, Catherine Thiéblemont, John Karavitis, Brian Hess, Paolo Caimi, Tatyana Feldman, Martin Hutchings, Anna Sureda, Edith Szafer‐Glusman, Marco Sacchi, Maria Jure‐Kunkel, Neeraj Adya, Christopher Chiu	2
13	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort breakdown → 2022 ·Blood ·Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, (unknown), Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, (unknown), Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia	124
14	PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 2022 ·HemaSphere ·Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Constantine S. Tam, Paolo Ghia, Carol Moreno, Neil E. Kay, Tanya Siddiqi, Edith Szafer‐Glusman, Cathy Zhou, Lynne Neumayr, (unknown), William G. Wierda, Tait D. Shanafelt	1
15	PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS 2021 ·Hematological Oncology ·(unknown), Ida H. Hiemstra, (unknown), (unknown), (unknown), Patricia Garrido Castro, (unknown), Roberto S Oliveri, (unknown), (unknown), Edith Szafer‐Glusman, Danita H. Schuurhuis, Julie Blædel, Tahamtan Ahmadi, Esther C.W. Breij, A. Kate Sasser, Maria Jure‐Kunkel	1
16	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Elizabeth A. Punnoose, Franklin Peale, Edith Szafer‐Glusman, Guiyuan Lei, Richard Bourgon, An D, Eugene S. Kim, Ping Zhang, Pedro Farinha, Randy D. Gascoyne, Francisco Muñoz, Maurizio Martelli, Anja Mottok, Gilles Salles, Laurie H. Sehn, John F. Seymour, Marek Trněný, Mikkel Z. Oestergaard, Kirsten Mundt, Umberto Vitolo	10
17	A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL 2017 ·Blood ·Edith Szafer‐Glusman, Juan Liu, Franklin Peale, Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, Günter Fingerle‐Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth A. Punnoose	1
18	BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL 2017 ·Blood ·Edith Szafer‐Glusman, Franklin Peale, Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, Elizabeth A. Punnoose	1
19	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer 2017 ·Annals of Oncology ·Marius Ilié, Edith Szafer‐Glusman, Véronique Hofman, Emmanuel Chamorey, Salomé Lalvée, Éric Selva, Sylvie Leroy, Charles‐Hugo Marquette, Marcin Kowanetz, (unknown), Elizabeth A. Punnoose, Paul Hofman	153
20	Role of Survivin in cytokinesis revealed by a separation-of-function allele 2011 ·Molecular Biology of the Cell ·Edith Szafer‐Glusman, Margaret T. Fuller, Maria Grazia Giansanti	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact